DrugMar 22, 2017
Synergy Rx 5-FLUOROURACIL IN VANICREAM, FLUOROURACIL in all strengths including 0.05%, 5% recall — FDA D-0527-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
Latest records
Latest recalls — page 1681
The newest recall records with useful source details are listed here.
DrugMar 22, 2017
Synergy Rx DICLOFENAC 3% and 5% LIP BALM and DICLOFENAC 5% SPF 30 LIP BALM recall — FDA D-0580-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx QUAD PEEL recall — FDA D-0568-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx QUAD BLEACHING CREAM recall — FDA D-0567-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx GENERIC VI PEEL recall — FDA D-0558-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx SUPREME BLEACHING CREAM recall — FDA D-0571-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx TRETINOIN CREAM in all strengths including: 0.1%, 0.05%, TRETINOIN GEL in all recall — FDA D-0588-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx FIRM AND FADE recall — FDA D-0557-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx HCG and HCG with resveratrol Human Chorionic Gonadotropin in different strengths recall — FDA D-0524-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx TRICHLOROACETIC ACID SOLUTION in all strengths including: 10%, 12%, 15 %, 20% recall — FDA D-0544-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Amerisource Health Services GlipiZIDE Extended-release tablets, 2.5 mg, 30-count carton recall — FDA D-0520-2017
Failed dissolution specifications: Glipizide 2.5 mg ER Tablets exceeded dissolution specification rates for the 10 hour testing point.
Class IIFDA: TerminatedAmerisource Health Services
DrugMar 22, 2017
Synergy Rx MALEK'S MAGIC recall — FDA D-0563-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Pharmedium Services Buffered Lidocaine, 1%, In Sodium Bicarbonate 8.4%, 1 mL Total Volume in recall — FDA D-0603-2017
Labeling; Label Mixup; outer packaging is incorrectly labeled as Buffered Lidocaine 1% instead of correctly as Buffered Lidocaine 0.9%
Class IIIFDA: TerminatedPharmedium Services, LLC
DrugMar 22, 2017
Synergy Rx DUO Cream recall — FDA D-0556-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
PROTONIX I.V. (pantoprazole sodium) for Injection, Equivalent to 40 mg pantoprazole per recall — FDA D-0516-2017
Subpotent Drug: Out of Specification (OOS) for potency at the 6-month stability time point.
Class IIIFDA: TerminatedPfizer Inc.
DrugMar 22, 2017
Synergy Rx ENHANCED RETIN ANTI-WRINKLE CREAM, ENHANCED RETIN ANTI-WRINKLE CREAM 0.1% recall — FDA D-0583-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx HCG in all strength including: 2,400, 9600,12,000 UNIT POWDER VIAL DROPS, HCG recall — FDA D-0584-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx HYDROQUINONE CREAM in all strengths including 4%, 5%,6%, 7%, 8%, HYDROQUINONE recall — FDA D-0547-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx CLARIFYING CREAM recall — FDA D-0553-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
Synergy Rx CLOBETASOL 0.05% IN OLEA BASE, CLOBETASOL 0.05% IN OROBASE, CLOBETASOL 0.05% recall — FDA D-0535-2017
Lack of Assurance of Sterility: There are also CGMP Deviations.
Class IIFDA: TerminatedSynergy Rx
DrugMar 22, 2017
G & W Laboratories Clindamycin Phosphate Topical Solution USP, 1% recall — FDA D-0519-2017
CGMP Deviations: an expired active ingredient was used in the manufacture of these recalled lots.
Class IIIFDA: TerminatedG & W Laboratories, Inc.
Medical DeviceMar 15, 2017
Merge Healthcare DR Systems Unity PACS software, now known as Merge Unity PACS recall — FDA Z-1426-2017
Reports were missing demographic header information when they were faxed to referring physicians.
Class IIFDA: TerminatedMerge Healthcare, Inc.
Medical DeviceMar 15, 2017
US Endoscopy Group Roth Net Polyp Retrieval recall — FDA Z-1416-2017
The firm was notified that the expiration date on the outer carton is different than the expiration date on the inner package. The expiration date is shorter than the actual expiration.
Class IIIFDA: TerminatedUS Endoscopy Group Inc.
Medical DeviceMar 15, 2017
Siemens Medical Solutions USA Biograph 6 TruePoint, Material Number 10097290 The Biograph recall — FDA Z-1423-2017
The mobile-specific instructions was not shipped to a limited population of Biograph Mobile systems.
Class IIFDA: TerminatedSiemens Medical Solutions USA Inc.
Browse by month
Recent recall archives
Browse recent months with enough recall history for useful comparison.
October 2026245 records · 4 categoriesSeptember 2026363 records · 4 categoriesAugust 2026302 records · 4 categoriesJuly 2026371 records · 4 categoriesJune 2026375 records · 4 categoriesMay 2026340 records · 4 categoriesApril 2026415 records · 4 categoriesMarch 2026190 records · 4 categoriesFebruary 2026331 records · 4 categoriesJanuary 2026212 records · 4 categoriesDecember 2025389 records · 4 categoriesNovember 2025326 records · 4 categories